Shaquille O'Neal credits Zepbound, a GLP-1 receptor agonist medication, with improving both his sleep apnea and weight loss. The basketball legend shared how the injectable drug helped him manage two interconnected health challenges that often plague people with obesity.
Sleep apnea occurs when airway collapse interrupts breathing during sleep, and it commonly develops alongside excess weight. O'Neal's experience reflects what sleep medicine specialists have long observed: weight reduction frequently alleviates sleep apnea symptoms because less throat tissue compresses the airway.
Zepbound (tirzepatide) works by mimicking glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide hormones. These naturally occurring chemicals regulate hunger and blood sugar. The medication slows stomach emptying, increases satiety, and reduces appetite-driven eating. Clinical trials show patients using GLP-1 medications lose 15 to 22 percent of body weight over 68 weeks, compared to 2.4 percent with placebo.
The connection between weight and sleep apnea runs both directions. Extra tissue around the neck narrows airways, triggering apnea events. Sleep deprivation from fragmented sleep then disrupts hormones controlling hunger and metabolism, making weight loss harder. Breaking this cycle offers compounding benefits.
Dr. Raj Dasgupta, a sleep medicine specialist at the University of Southern California, notes that weight loss represents one of the most effective treatments for obstructive sleep apnea. Even modest reductions improve breathing and sleep quality.
O'Neal's public disclosure reflects broader physician and patient interest in GLP-1 medications for conditions beyond diabetes. Medical associations continue evaluating whether insurers should cover these drugs for weight management independent of diabetes diagnosis. The medications carry side effects including nausea, vomiting, and